Dawn Svoronos joined the Board of Directors of Galapagos as a Non-Executive Independent Director in July 2025. She brings over 30 years of global biopharmaceutical experience, with a strong track record in commercial leadership. Mrs. Svoronos spent 23 years at Merck, known as MSD outside of the United States and Canada, where she held positions of increasing responsibility. As President of Europe and Canada, she successfully led the post-merger integration of Merck and Schering-Plough and oversaw operations across 30 European markets. Her previous roles included President of Merck Canada, Vice President of Asia Pacific, and Vice President of Global Marketing for the Arthritis, Analgesics, and Osteoporosis franchises, where she was responsible for global brand strategy, market intelligence, pricing, and lifecycle management.
She currently serves as Chair of the Board of Xenon Pharmaceuticals and sits on the Boards of Adverum Biotechnologies, and AgNovos Bioscience.
Ms. Svoronos is a Canadian citizen and holds a B.A. in English and French Literature from Carleton University.
